Topic Lifecycle: Dormant
This topic is currently dormant in the news cycle. It was last covered on Thursday 20 August 2026 and has not appeared in recent broadcasts.
Coverage trend (last 30 days)
How much coverage this topic got from each channel over the past month.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Recent stories
The latest story timelines linked to this topic, newest activity first.
What was reported
A plain summary of this topic, built from the channels that covered it.
On 6 July 2026, the weight loss drug Wegovi became available in pill form in the UK via private prescription. The once-daily tablet contains semaglutide, the same active ingredient as the injectable version, and is intended to suppress appetite. It is approved for adults with a BMI of 30 or higher, or a BMI of at least 27 with a weight-related condition. The pills are not currently available on the NHS. They can be obtained from high street and online pharmacies at a similar price to the injections. Coverage noted potential side effects including headaches, nausea, diarrhoea, constipation, and rarer risks such as eye problems and pancreatitis. Some channels highlighted concerns about misuse, counterfeiting, and the need to address the broader food environment. The manufacturer, Novo Nordisk, stated that producing the pill is not cheaper than the injections and emphasised education to prevent misuse.
Key Claims by Channel
| Claim | Channel 5 | BBC One | ITV |
|---|---|---|---|
| Wegovi weight-loss drug became available in pill form in the UK on 6 July 2026. | |||
| The pill is available only via private prescription, not on the NHS. | |||
| The pill is approved for people with a BMI of 30 or higher, or a BMI of at least 27 with a weight-related condition. | · | ||
| The pill costs about the same as the injectable version. | · | ||
| The pill does not require refrigeration, unlike the injections. | · | · | |
| Side effects include headaches, nausea, diarrhoea, constipation, and more serious risks such as eye problems and pancreatitis. | · | · | |
| Novo Nordisk's CEO said producing the pill is not cheaper than producing the injections. | · | · | |
| Novo Nordisk is partnering with authorities and law enforcement to prevent counterfeiting of the pills. | · | · | |
| The pills could increase the risk of misuse by people with eating disorders or for cosmetic reasons; Novo Nordisk emphasised education to address this. | · | · | |
| An expert commented that more must be done to change the food environment to prevent obesity. | · | · | |
| The medicines regulator has approved the pill form. | · | · | |
| Counterfeit versions are a concern because pills are easier to fake than injections. | · | · |
This is a cross-channel consensus summary, not an objective account. Consensus can be uniformly wrong, or omit what only one channel covered.
Timeline
Where this topic appeared. Cells show coverage time and are darker when there was more coverage.
| Date | Channel 5 | BBC News | BBC One | BBC Two | Channel 4 | GB News | ITV | Sky News |
|---|---|---|---|---|---|---|---|---|
| Thursday 20 August 2026 | — | — | 2m 24s 2.5% | — | — | — | — | — |
| Thursday 23 July 2026 | — | — | — | — | — | — | 2m 18s 3.4% | — |
| Monday 6 July 2026 | 6m 15s 14.8% | — | 2m 38s 4.6% | — | — | — | 6m 2s 9.6% | — |
| Wednesday 1 July 2026 | 2m 26s 6.6% | — | — | — | — | — | — | — |